Skip to content

Effects of Whey Protein in Type 2 Diabetics

Effect of Chronic Administration of Whey Protein on HbA1c and Postprandial Glycemia in Type 2 Diabetic Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01944449
Acronym
WHEY-T2D
Enrollment
60
Registered
2013-09-17
Start date
2013-09-30
Completion date
2016-03-31
Last updated
2017-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 diabetes (T2D), Whey Protein Concentrate (WPC)

Brief summary

The objectives of this study are to examine the effects of chronic, (12 weeks) administration of Whey protein on HbA1c, and postprandial glucose (PPG).

Detailed description

Whey protein that accounts for 20% of whole milk protein seems to induce insulinotropic /β-cell-stimulating and glucose lowering effects via bioactive peptides generated during its gastrointestinal digestion. These bioactive peptides stimulate the release of GLP-1, serve as endogenous inhibitors of DPP-4 and cause inhibitory activity against α-glucosidase activity, which might be an additional mechanism accounting for the glucose lowering effects of Whey. In the investigators previous study, the acute administration with Whey protein resulted in postprandial insulinotropic and glucose lowering effects in type 2 diabetic subjects. This was associated with increased postprandial response of the total-GLP-1 and of intact-GLP-1, suggesting that the peptides generated from Whey protein may have dual beneficial effects (increasing incretin production and decreasing incretin degradation by DPP-4) on glycemia regulation in subjects with type 2 diabetes. Addition of Whey protein to the meal, significantly decreased PPG in healthy and in type 2 diabetic subjects and there are also clinical evidence in non-diabetics individuals, that acute and chronic administration of Whey protein has antihypertensive activity. The effect of chronic administration of Whey protein on HbA1c and PPG have not been examined previously in type 2 diabetics.

Interventions

DIETARY_SUPPLEMENTWhey Protein (WPC) at breakfast

The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.

DIETARY_SUPPLEMENTOther Protein Sources at breakfast

The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.

DIETARY_SUPPLEMENTLow Protein at breakfast

The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.

Sponsors

Hospital de Clinicas Caracas
CollaboratorOTHER
Tel Aviv University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Type 2 diabetes patients 2. HbA1C \> 7.5% 3. Duration of diabetes: \< 20 years 4. Subjects ≥ 30 and ≤70 years of age 5. BMI: 22 to 35 kg/m2 6. All oral antidiabetic treatments will be allowed. No insulin 7. Normal liver and kidney function 8. Normal thyroid function 9. Stable physical activity pattern during the three months immediately preceding study 10. No metabolic disease other than diabetes 11. Normal TSH and FT4 levels 12. Acceptable health beside diabetes based on interview, medical history, physical examination, and laboratory tests 13. Read and understood the informed consent form and signed it voluntarily

Exclusion criteria

1. Type 1 diabetes 2. Treatment with Insulin 3. Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, malignant disease 4. Abnormal liver function tests defined as an increase by a factor of at least 2 above the upper normal limit of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) 5. Pregnancy or lactation 6. Illicit drug abuse or alcoholism 7. Subjects taking anoretic drugs during the month immediately prior to study 8. Subjects on steroid treatment 9. Those with major illnesses, liver, heart, kidney, lung, infectious, neurological, psychiatric, immunological or neoplastic diseases, 10. Those with eating disorders 11. Known hypersensitivity to milk components 12. Subjects after bariatric surgery, will be excluded 13. Subjects known by the principal investigator to be unable to cooperate for any reason.

Design outcomes

Primary

MeasureTime frameDescription
Fasting circulating levels of HbA1c3 monthIn all 60 subjects we will evaluate at baseline and after three month of consumption of WPC or Protein from other source or Low Protein at breakfast the effects on fasting circulating levels of HbA1c.

Secondary

MeasureTime frameDescription
Postprandial Glucose3 monthIn all 60 subjects we will evaluate the effect of consumption of WPC or Protein from other source or Low Protein at breakfast on postprandial glucose
Body Weight3 monthsIn all 60 subjects we will evaluate at baseline and after three month of consumption of WPC or Protein from other source or Low Protein at breakfast the effects on body weight

Countries

Israel, Venezuela

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026